Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I−/− iPSC-derived β cells for cell therapy of type 1 diabetes
Raniero Chimienti(Istituti di Ricovero e Cura a Carattere Scientifico), Lorenzo Piemonti(Vita-Salute San Raffaele University), Paolo Monti(IRCCS Ospedale San Raffaele), Valeria Sordi(Vita-Salute San Raffaele University), Angelo Lombardo(Vita-Salute San Raffaele University), Alessandro Cospito(IRCCS Ospedale San Raffaele), Mauro Malnati(Vita-Salute San Raffaele University), Silvia Pellegrini(Vita-Salute San Raffaele University), Fabio Manenti(IRCCS Ospedale San Raffaele), S. Torchio(Vita-Salute San Raffaele University), Tania Baccega(The San Raffaele Telethon Institute for Gene Therapy)
Cited by 2
Related Papers
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains
|Immunity|1995|574
CD46 Is a Cellular Receptor for Human Herpesvirus 6
|Cell|1999|525